Biontech Se

Biontech Ag

Johannes Gutenberg-Universität Mainz

Biontech Protein Therapeutics Gmbh

Tron—translationale Onkologie An Der Univresitätsmedizin Der Johannes Gutenberg-Universität Mainz Gemeinnützige Gmbh

Tron—translationale Onkologie An Der Universitátsmedizin Der Johannes Gutenberg—universitÄt Mainz Gemeinnützige Gmbh

Thomas Michael Hiller

Ugur Sahin

Michael Koslowski

Ozlem Tureci

Özlem Türeci

Heinrich Haas

Thorsten Klamp

Sebastian Hörner

Jens Schumacher

Isaac Hernan Esparza Borquez

Ferdia Bates

The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.

Preparation and storage of liposomal RNA formulations suitable for therapy

The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject.

Tumor vaccination involving a humoral immune response against self-proteins

Growing community of inventors

Mainz, Germany

Thomas Michael Hiller